Editas Medicine (NASDAQ: EDIT) halts sales under TD Cowen ATM prospectus
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Editas Medicine, Inc. filed a current report describing a change to its equity distribution plans with TD Securities (USA) LLC, doing business as TD Cowen. The company has suspended and terminated the existing prospectus supplement for its “at-the-market” stock offering program under the Sales Agreement.
Editas states it will not sell additional common stock through this program unless and until a new prospectus or prospectus supplement is filed and, if needed, a new registration is declared effective by the SEC. The underlying Sales Agreement with TD Cowen remains in effect.
As of May 26, 2026, Editas had issued and sold 14,327,365 shares of common stock under this at-the-market program, generating aggregate gross sale proceeds of $43.9 million before sales commissions and offering expenses.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
ATM shares sold: 14,327,365 shares
ATM gross proceeds: $43.9 million
Sales Agreement date: May 14, 2021
+2 more
5 metrics
ATM shares sold
14,327,365 shares
Common stock issued under at-the-market program as of May 26, 2026
ATM gross proceeds
$43.9 million
Aggregate gross sale proceeds before commissions and expenses as of May 26, 2026
Sales Agreement date
May 14, 2021
Original date of Sales Agreement with TD Cowen
Sales Agreement amendments
February 28, 2024 and March 5, 2025
Amendment dates to the Sales Agreement
Prospectus supplement suspension date
May 26, 2026
Date Editas suspended and terminated the ATM prospectus supplement
Key Terms
at-the-market offering program, prospectus supplement, Sales Agreement, Registration Statement on Form S-3, +1 more
5 terms
at-the-market offering program financial
"the Company may offer and sell shares of its common stock... under an “at-the-market” offering program"
An at-the-market offering program lets a company sell newly issued shares directly into the open market at current trading prices through a broker, rather than issuing a large block of stock all at once. It matters to investors because it provides the company a flexible way to raise cash over time, which can dilute existing shares gradually and affect earnings per share and stock price depending on how much and when shares are sold—think of it as a faucet the company can open or close to add supply to the market.
prospectus supplement regulatory
"it was suspending and terminating the prospectus supplement, dated March 21, 2025"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Sales Agreement financial
"as amended, the “Sales Agreement”), and pursuant to which the Company may offer and sell shares"
A sales agreement is a written contract that sets out the terms for selling goods, services, or assets, specifying price, delivery, payment schedule and responsibilities of each side. For investors it matters because it creates a predictable stream of revenue or cash obligations, clarifies timing and risk, and can change a company’s value or forecasts much like a signed order turns a customer’s verbal intent into a firm commitment.
Registration Statement on Form S-3 regulatory
"Post-Effective Amendment No.1 to the Registration Statement on Form S-3 (333-277471)"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did Editas Medicine (EDIT) change in its stock offering program?
Editas Medicine suspended and terminated its existing prospectus supplement for an at-the-market stock offering program with TD Cowen. The Sales Agreement remains in effect, but no further sales will occur until a new prospectus or registration is effective with the SEC.
Is Editas Medicine (EDIT) ending its relationship with TD Cowen?
Editas Medicine is not ending its relationship with TD Cowen. The company states the Sales Agreement with TD Cowen remains in full force and effect. Only the current prospectus supplement for the at-the-market program has been suspended and terminated.
How much has Editas Medicine (EDIT) raised through its at-the-market offering?
Editas Medicine reports raising aggregate gross sale proceeds of $43.9 million through its at-the-market offering program. This total comes from issuing and selling 14,327,365 shares of common stock, before deducting sales commissions and offering expenses, as of May 26, 2026.
What is the regulatory status of Editas Medicine’s (EDIT) offering documents?
Editas Medicine has suspended and terminated the prior prospectus supplement for its at-the-market offering. The company notes that future sales under this program require a new prospectus or prospectus supplement and, if applicable, a new registration declared effective by the SEC.